Home » Stocks » HZNP

Horizon Therapeutics PLC (HZNP)

Stock Price: $92.14 USD 4.40 (5.01%)
Updated May 14, 2021 4:00 PM EDT - Market closed
After-hours: $92.10 -0.04 (-0.04%) May 14, 5:43 PM
Market Cap 20.71B
Revenue (ttm) 2.19B
Net Income (ttm) 280.04M
Shares Out 224.77M
EPS (ttm) 1.25
PE Ratio 73.65
Forward PE 19.80
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $92.14
Previous Close $87.74
Change ($) 4.40
Change (%) 5.01%
Day's Open 88.32
Day's Range 87.74 - 92.41
Day's Volume 1,393,193
52-Week Range 45.01 - 97.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

DUBLIN--(BUSINESS WIRE)--Horizon ranked #1 in overall corporate reputation among U.S. patient groups that reported working with the company.

2 days ago - Business Wire

As the market gets back to normal, it's a great time to explore the pharma stocks that got lost in the vaccine frenzy of the past year. The post 7 of the Best Pharma Stocks to Buy Now appeared first on ...

Other stocks mentioned: ALLK, IBRX, IMAB, MNMD, SAGE, SWTX
4 days ago - InvestorPlace

As investors were so righteously reminded on Friday, many of the day-to-day Wall Street prognostications and strategy calls are almost always “best guesses” or data-based “assumptions.

Other stocks mentioned: FCX, TLRY, Z
5 days ago - 24/7 Wall Street

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in May: Bank of America Securities 2021 Health Care Confere...

1 week ago - Business Wire

DUBLIN--(BUSINESS WIRE)--New analysis of UPLIZNA® (inebilizumab-cdon) for neuromyelitis optica spectrum disorder (NMOSD) has been published.

1 week ago - Business Wire

Horizon (HZNP) misses estimates for earnings in the first quarter of 2021 while revenues beat the same.

1 week ago - Zacks Investment Research

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Elizabeth H.Z. Thompson, Ph.D., executive vice president, research and development, has been named a 2021 Healthcare...

1 week ago - Business Wire

Horizon Therapeutics reported a mixed quarter Wednesday, but raised its sales target for 2021. Still, HZNP stock dipped after the open.

1 week ago - Investors Business Daily

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of -57.14% and 4.88%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Shares of Horizon Therapeutics (NASDAQ:HZNP) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share were down 92.50% year over year to $0.03, which missed the estimat...

1 week ago - Benzinga

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc Reports First-Quarter 2021 Financial Results; Updating Full-Year 2021 Guidance to Incorporate Recently Acquired Viela Bio

1 week ago - Business Wire

Horizon Therapeutics (HZNP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

2 weeks ago - Zacks Investment Research

Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc ranked #4 in overall corporate reputation among pharmaceutical and biotech companies.

2 weeks ago - Business Wire

CHARLOTTESVILLE, Va., April 21, 2021 /PRNewswire/ -- HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has identified a second drug target for the treatment of gout un...

3 weeks ago - PRNewsWire

NAARDEN, The Netherlands & MUNICH--(BUSINESS WIRE)--Forbion, a leading European life sciences venture capital firm, today announces the final close of its Forbion Growth Opportunities Fund I (“Forbion G...

3 weeks ago - Business Wire

Horizon Therapeutics's shares are up almost 200% over the past 12 months, buoyed by mind-boggling sales of its new blockbuster drug.

4 weeks ago - The Motley Fool

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics today announced new UPLIZNA® (inebilizumab-cdon) data being presented at the American Academy of Neurology 2021 Annual Meeting.

4 weeks ago - Business Wire

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced pooled data from the TEPEZZA® (teprotumumab-trbw) clinical trials are published in The Lancet Diabetes & Endocrinology.

4 weeks ago - Business Wire

Biotech stock Horizon Therapeutics is set up below a buy point, ahead of earnings, after soaring 102% in 2020. Can it do it again?

1 month ago - Investors Business Daily

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its first-quarter 2021 financial results will be released on Wednesday, May 5, 2021. Following the announcement, Hor...

1 month ago - Business Wire

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced the publication of data from the first randomized controlled clinical trial (RCT) of KRYSTEXXA (pegloticase injection) concomit...

1 month ago - Business Wire

Horizon Therapeutics has a clear path to significant sales growth.

Other stocks mentioned: ABBV, BMY, PFE, SGEN, VRTX
1 month ago - The Motley Fool

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announces new NMOSD data being presented at the American Academy of Neurology's 73rd Annual Meeting.

1 month ago - Business Wire

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics to resupply the market with TEPEZZA® (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED) beginning in April.

1 month ago - Business Wire

DEERFIELD, Ill.--(BUSINESS WIRE)--Horizon Therapeutics (Nasdaq: HZNP) and the Cubs today announced a Legacy Partnership that includes a Cubs STEAM Program, presented by Horizon, which will include an in...

1 month ago - Business Wire

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a clinical trial that will evaluate a monthly dosing regimen of 16 mg of KRYSTEXXA (peg...

1 month ago - Business Wire

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its strategic partner Mitsubishi Tanabe Pharma Corporation (MTPC) has received manufacturing and marketing approval ...

1 month ago - Business Wire

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP), in partnership with MIT Solve, a marketplace for social impact innovation, today announced it has created a first-of-its-kind annual glo...

1 month ago - Business Wire

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has completed the acquisition of Viela Bio, Inc. (Nasdaq: VIE) (“Viela”). “The Viela acquisition provides multipl...

Other stocks mentioned: VIE
2 months ago - Business Wire

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced it ranked No. 1 on the Fortune Best Workplaces in Biopharma 2021 list. This is the fifth consecutive year Horizon has bee...

2 months ago - Business Wire

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been recognized as one of the Best Workplaces in Ireland 2021 by Great Place to Work Ireland, ranking No. 12 ...

2 months ago - Business Wire

The shares of Horizon Therapeutics PLC  (NASDAQ:HZNP)  are down 3.4% at $91.29 at last check.

2 months ago - Schaeffers Research

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in March: Cowen and Company 41st Annual Health Care Confere...

2 months ago - Business Wire

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of a month-long virtual storytelling experience to elevate the diverse voices and faces of the rare disease co...

2 months ago - Business Wire

Horizon (HZNP) beats earnings and sales estimates in the fourth quarter of 2020.

2 months ago - Zacks Investment Research

The biopharmaceutical company released its latest quarterly update.

2 months ago - The Motley Fool

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 21.90% and 7.36%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Horizon Therapeutics (NASDAQ:HZNP) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share rose 128.57% over the past year to $1.28, which beat the esti...

2 months ago - Benzinga

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc Reports Record Fourth-Quarter and Full-Year 2020 Financial Results; Announces Full-Year 2021 Guidance

2 months ago - Business Wire

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced results of a new Thyroid Eye Disease (TED) quality of life assessment presented at the NANOS Annual Meeting.

2 months ago - Business Wire

Paulson & Co., the firm led by John Paulson (Trades, Portfolio), disclosed this week that its top five buys during the fourth quarter of 2020 were in Horizon Therapeutics PLC (NASDAQ:HZNP), Barrick Gold...

Other stocks mentioned: ALXN, GOLD, RP, THRY
2 months ago - GuruFocus

Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

NEW YORK--(BUSINESS WIRE)--Horizon Therapeutics expands partnership with Medidata to speed clinical trial start-up and completion, using a broad range of technology solutions.

3 months ago - Business Wire

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its fourth-quarter and full-year 2020 financial results will be released on Wednesday, Feb. 24, 2021. Following the ...

3 months ago - Business Wire

Horizon Therapeutics (HZNP) is set to buy Viela Bio for $3.05 billion to expand its pipeline and accelerate growth.

Other stocks mentioned: VIE
3 months ago - Zacks Investment Research

Horizon Pharma saw an improvement in its IBD SmartSelect Composite Rating Monday, from 94 to 96. The post Horizon Pharma Sees Rising Composite Rating To 96 appeared first on Investor's Business Daily.

3 months ago - Investors Business Daily

Horizon Therapeutics PLC (NASDAQ: HZNP), a rare and rheumatic diseases drug company, announced a multibillion-dollar deal Monday to snap up Viela Bio Inc (NASDAQ: VIE). What Happened: Horizon said it ha...

3 months ago - Benzinga

Horizon Therapeutics Plc said Monday it has agreed to acquire Viela Bio Inc. for $53 a share in cash, or an equity value of about $3.05 billion. The deal is expected to close by the end of the first qua...

Other stocks mentioned: VIE
3 months ago - Market Watch

About HZNP

Horizon Therapeutics Public Limited Company focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. It operates in two segments, Orphan and Inflammation. Its medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare lysosomal storage disorder; ACTIMMUNE for chroni... [Read more...]

Industry
Drug Manufacturers-General
IPO Date
Jul 28, 2011
Stock Exchange
NASDAQ
Ticker Symbol
HZNP
Full Company Profile

Financial Performance

In 2020, HZNP's revenue was $2.20 billion, an increase of 69.26% compared to the previous year's $1.30 billion. Earnings were $389.80 million, a decrease of -31.98%.

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for HZNP stock is "Buy." The 12-month stock price forecast is 114.18, which is an increase of 23.92% from the latest price.

Price Target
$114.18
(23.92% upside)
Analyst Consensus: Buy